Levetiracetam in stiff-person syndrome
- 211 Downloads
We studied the effects of oral levetiracetam (LEV) (500 mg twice daily) in three women with stiff-person syndrome in a single-blind, placebo-controlled study. The severity of muscle rigidity and of paroxysmal symptoms was assessed by EMG and clinically by a rating scale of 0–4 and by the Patients Global Impressions Scale. LEV was well tolerated. On active treatment all patients improved as assessed by any of the objective or subjective outcome measures. No response was noticed on placebo. Our data indicate that in patients with SPS, LEV is well tolerated and has a therapeutic role in the management of both muscle stiffness and life-threatening paroxysmal respiratory spasms.
Key wordsstiff-person syndrome levetiracetam clinical trial
Unable to display preview. Download preview PDF.
- 2.Guy W (1976) (Ed) ECDEV assessment manual for psychopharmacology. Revised ed. Bethesda, MD: U.S. Department of Health, Education and WelfareGoogle Scholar
- 4.Lynch BA, Lambeng N, Nocka K, et al. (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 10:19861−19866Google Scholar
- 9.Rigo JM, Hans G, Nguyen L, et al. (2002) The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol 13:6659−6672Google Scholar